2005—2014年中国前列腺癌流行特征

刘灿; 李想; 王雷; 沈婉莹; 熊文婧; 让蔚清

doi:10.16462/j.cnki.zhjbkz.2021.07.013

2005—2014年中国前列腺癌流行特征

doi: 10.16462/j.cnki.zhjbkz.2021.07.013

刘灿¹,
李想¹,
王雷¹,
沈婉莹¹,
熊文婧²,
让蔚清^1, ,

1.
421001 衡阳，南华大学公共卫生学院预防医学系
2.
421001 衡阳，衡阳市中医医院肾病科

基金项目:

国家自然科学基金 81673107

详细信息

通讯作者:
让蔚清，E-mail: nhurwq@126.com

中图分类号: R737.25
计量
- 文章访问数: 552
- HTML全文浏览量: 180
- PDF下载量: 69
- 被引次数: 0
出版历程
- 收稿日期: 2020-07-06
- 修回日期: 2020-10-16
- 网络出版日期: 2021-08-13
- 刊出日期: 2021-07-10

Chinese prostate cancer epidemiological characteristics from 2005 to 2014

1.
Department of Preventive Medicine, School of Public Health, University of South China, Hengyang 421001, China
2.
Department of Nephrology, Hengyang Hospital of Traditional Chinese Medicine, Hengyang 421001, China

Funds:

National Natural Science Foundation of China 81673107

More Information

Corresponding author: RANG Wei-qing, E-mail: nhurwq@126.com

摘要

摘要: 目的分析《中国肿瘤登记年报》中2005—2014年男性前列腺癌发病率与死亡率的变化趋势，为开展前列腺癌防治提供参考。方法利用Excel 2019软件提取2005—2014年中国男性前列腺癌发病率和死亡率的全部数据；运用Joinpoint回归分析模型分析2005—2014年中国男性前列腺癌发病率和死亡率的变化趋势。结果 2005—2014年中国前列腺癌标化发病率和标化死亡率整体呈上升趋势，城市的两标化率均高于农村。全国标化发病率由2005年的5.8/10万增至2014年的8.1/10万，增加39.65%；全国标化死亡率由2005年的2.3/10万增至2014年的2.4/10万，增加4.34%。城市、农村男性标化发病率平均每年的增长速度分别为1.40%、6.10%；城乡标化死亡率平均每年的增长速度分别为2.51%、2.62%。60岁后的男性前列腺癌的发病率和死亡率随年龄的增长而增长，中国60岁以上的男性是前列腺癌防治的重点人群。结论与2005年相比，2014年中国前列腺癌的发病及死亡率趋势呈现增加，应积极制定并完善前列腺癌的防治措施，重点加强对60岁以上男性的综合预防工作。
- 前列腺癌 /
- 发病率 /
- 死亡率 /
- Joinpoint回归模型
Abstract: Objective To analyze the prevalence trend of male prostate cancer morbidity and mortality from 2005 to 2014 in the "China Cancer Registry Annual Report" so as to provide reference for the prevention and treatment of prostate cancer. Methods All data of prostate cancer morbidity and mortality in Chinese men from 2005 to 2014 were extracted by using Excel 2019. Joinpoint regression model was used to analyze the changing trend of prostate cancer morbidity and mortality in Chinese men from 2005 to 2014. Results The overall standardized incidence rate and the standardized mortality rate of prostate cancer in Chinese men were on the rise from 2005 to 2014, and the two standardized rates of urban were greater than that of rural. The standardized incidence rate increased by 39.65% from 2005(5.8/100 000) to 2014(8.1/100 000). The standardized mortality rate increased by 4.34% from 2005(2.3/100 000) to 2014(2.4/100 000). The average annual percent change of standardized incidence for urban and rural men rates were 1.4% and 6.1% respectively. The average annual percent change of standardized mortality for urban and rural men were 2.51% and 2.62% respectively. The morbidity and mortality of prostate cancer increased significantly with age in Chinese men after the age of 60. Men over the age of 60 have been the main population for the prevention and treatment of prostate cancer. Conclusions Compared with 2005, the trend of prostate cancer morbidity and mortality in China has showed a significant increase in 2014. It is necessary to formulate and improve prophylactic and preventive measures actively for prostate cancer. Strengthening comprehensive prevention for men over 60 years of age should be stressed.
- Prostate cancer /
- Morbidity /
- Mortality /
- Joinpoint regression model

HTML全文

图 1 2005—2014年中国男性前列腺癌标化发病率变化趋势

注：^a P＜0.05。

Figure 1. Trends in the standardized incidence in prostate cancer for Chinese men from 2005 to 2014

下载: 全尺寸图片幻灯片

图 2 2005—2014全国男性前列腺癌年龄别发病率变化趋势

注：^a P＜0.05。

Figure 2. Trends in age-specific incidence of prostate cancer for Chinese men from 2005 to 2014

下载: 全尺寸图片幻灯片

图 3 2005—2014年全国男性前列腺癌标化死亡率变化趋势

注：^a P＜0.05。

Figure 3. Trends in the standardized mortality in prostate mortality for Chinese men from 2005 to 2014

下载: 全尺寸图片幻灯片

图 4 2005—2014全国男性前列腺癌年龄别死亡率变化趋势

注：^a P＜0.05。

Figure 4. Trends in age-specific mortality of prostate cancer for Chinese men from 2005 to 2014

下载: 全尺寸图片幻灯片

表 1 2005—2014年中国男性前列腺癌发病率的APC(%)和AAPC(%)

Table 1. APC(%) and AAPC(%) of prostate cancer incidence for Chinese men from 2005 to 2014

分组	年度变化			平均年度变化
分组	APC(95% CI)值	t值	P值	AAPC(95% CI)值	t值	P值
全国	-0.83(-1.92~0.27)	-1.750	0.118	-0.83(-1.92~0.27)	-1.750	0.118
城市	1.40(0.49~2.31)	3.552	0.007	1.40(0.49~2.31)	3.552	0.007
农村	6.10(4.26~9.69)	6.097	< 0.001	6.10(4.26~9.69)	6.097	< 0.001

下载: 导出CSV

表 2 2005—2014年中国男性前列腺癌标化发病率和标化死亡率(/10万)

Table 2. The standardized incidence rates and the standardized mortality of prostate cancer for Chinese men from 2005 to 2014 (/100 000)

年份(年)	标化发病率			标化死亡率
年份(年)	城市	农村	全国	城市	农村	全国
2005	6.7	2.3	5.8	2.5	1.5	2.3
2006	7.2	2.4	6.3	2.4	1.4	2.2
2007	7.6	2.6	6.6	2.6	1.7	2.5
2008	7.8	2.7	6.8	2.6	1.3	2.4
2009	8.2	2.2	6.4	3.0	1.4	2.6
2010	7.7	2.4	7.7	3.0	1.4	2.5
2011	7.8	3.2	7.8	2.9	1.6	2.6
2012	8.1	3.4	8.1	2.9	1.7	2.4
2013	8.1	3.5	8.1	3.0	1.6	2.4
2014	8.1	3.7	8.1	2.9	1.7	2.4

下载: 导出CSV

表 3 2005—2014年中国男性前列腺癌死亡率的APC(%)和AAPC(%)

Table 3. APC(%) and AAPC (%) of prostate cancer incidence for Chinese men from 2005 to 2014

年份(年)	年度变化			平均年度变化
年份(年)	APC(95% CI)值	t值	P值	AAPC(95% CI)值	t值	P值
全国
2005—2009	3.53(-1.54~8.86)	1.779	0.135
2009—2014	-1.53(-3.39~0.37)	-2.080	0.092
2005—2014				0.69(-1.19~2.60)	0.715	0.475
城市
2005—2009	5.79(2.29~9.41)	4.297	0.008
2009—2014	-0.04(-1.44~1.37)	0.079	0.940
2005—2014				2.51(1.20~3.84)	3.772	< 0.001
农村
2005—2014	2.62(0.68~4.59)	3.129	0.014	2.62(0.68~4.59)	3.129	0.014

下载: 导出CSV

参考文献(19)

[1]	Arcangeli S, Pinzi V, Arcangeli G. Epidemiology of prostate cancer and treatment remarks[J]. World J Radiol, 2012, 4(6): 241-246. DOI: 10.4329/wjr.v4.i6.241.
[2]	王宁, 刘硕, 杨雷, 等. 2018全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2019, 5(1): 87-97. DOI: 10.12151/JMCM.2019.01-10. Wang N, Liu S, Yang L, et al. Interpretation on the report of global cancer statistics 2018[J]. Journal of Multidiscipinary Cancer Management, 2019, 5(1): 87-97. DOI: 10.12151/JMCM.2019.01-10.
[3]	Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries[J]. Int J Urol, 2018, 25(6): 524-531. DOI: 10.1111/iju.13593.
[4]	陈金东. 中国各类癌症的发病率和死亡率现状及发展趋势[J]. 遵义医学院学报, 2018, 41(6): 653-662. DOI: 10.14169/j.cnki.zunyixuebao.2018.0134. Chen JD. Trends of cancer incidence and mortality in China[J]. Journal of Zunyi Medical University, 2018, 41(6): 653-662. DOI: 10.14169/j.cnki.zunyixuebao.2018.0134.
[5]	Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.
[6]	顾秀瑛, 郑荣寿, 张思维, 等. 2000-2014年中国肿瘤登记地区前列腺癌发病趋势及年龄变化分析[J]. 中华预防医学杂志, 2018, 52(6): 586-592. DOI: 10.3760/cma.j.issn.0253-9624.2018.06.006. Gu XY, Zheng RS, Zhang SW, et al. Analysis on the trend of prostate cancer incidence and age change in cancer registration areas of China, 2000 to 2014[J]. Chin J Prev Med, 2018, 52(6): 586-592. DOI: 10.3760/cma.j.issn.0253-9624.2018.06.006.
[7]	丁雅妮, 刘晴, 张庆军. 1992-2017年中国男性前列腺癌的死亡率趋势: APC模型分析[J]. 公共卫生与预防医学, 2020, 31(1): 25-28. DOI: 10.3969/j.issn.1006-2483.2020.01.006. Ding YN, Liu Q, Zhang QJ. Trends in prostate cancer mortality in Chinese men from 1992 to 2017: an APC model analysis[J]. J of Pub Health and Prev Med, 2020, 31(1): 25-28. DOI: 10.3969/j.issn.1006-2483.2020.01.006.
[8]	赫捷, 陈万青. 中国肿瘤登记年报(2016)[M]. 北京: 清华大学出版社, 2017: 10-25. Hao J, Chen WQ. Chinese cancer registry annual report(2016)[M]. Beijing: Tsinghua University Press, 2017: 10-25.
[9]	Kim HJ, Fay MP, Feuer EJ. Permutation tests for Joinpoint regression with applications to cancer rates[J]. Stat Med, 2000, 19(3): 335-351. DOI:10.1002/(sici)1097-0258(20000215)19:3<335:aid-sim336>3.0.co;2-z.
[10]	Salem S, Salahi M, Mohseni M. Major dietary factors and prostate cancer risk: a prospective multicenter casecontrol study[J]. Nutr Cancer, 2011, 63(1): 21-27. DOI: 10.1080/01635581.2010.516875.
[11]	李蕊岑, 陈吉祥, 雷亚莉, 等. 前列腺癌相关危险因素研究进展[J]. 实用医院临床杂志, 2019, 16(1): 197-199. DOI: 10.3969/j.issn.1672-6170.2019.01.063. Li RC, Chen JX, Lei YL, et al. Research progresson risk factors of prostate cancer[J]. Practical Journal of Clinical Medicine, 2019, 16(1): 197-199. DOI: 10.3969/j.issn.1672-6170.2019.01.063.
[12]	韩苏军. 中国前列腺癌发病及死亡现状和流行趋势分析[D]. 北京: 北京协和医学院, 2015. Han SJ. Analysis of the status and trends of prostate cancer incidence and mortality in China[D]. Beijing: Peking Union Medical College, 2015.
[13]	Feletto E, Bang A, Cole-Clark D. An examination of prostate cancer trends in Australia, England, Canada and USA: is the Australian death rate too high?[J]. World J Urol, 2015, 33(11): 1677-1687. DOI: 10.1007/s00345-015-1514-7.
[14]	齐金蕾, 王黎君, 周脉耕, 等. 1990-2013年中国男性前列腺癌疾病负担分析[J]. 中华流行病学杂志, 2016, 37(6): 778-782. DOI: 10.3760/cma.J.issn.0254-6450.2016.06.007. Qi Jl, Wang LJ, Zhou MG, et al. Disease burden of prostate cancer among men in China, from 1990 to 2013[J]. Chin J Epidemiol, 2016, 37(6): 778-782. DOI: 10.3760/cma.J.issn.0254-6450.2016.06.007.
[15]	戴亮, 关晓海. 前列腺癌的相关危险因素分析[J]. 中国医药, 2012, 7(11): 1481-1484. DOI: 10.3760/cma.j.issn.1673-4777.2012.11.062. Dai L, Guan XH. Analysis of risk factors related to prostate cancer[J]. China Medicine, 2012, 7(11): 1481-1484. DOI: 10.3760/cma.j.issn.1673-4777.2012.11.062.
[16]	彭鹏, 龚杨明, 鲍萍萍, 等. 中国2008年前列腺癌发病、死亡和患病情况的估计及预测[J]. 中华流行病学杂志, 2012, 33(10): 1056-1059. DOI:10.3760/cma.J.issn.0254-6450.2012.10.014. Peng P, Gong YM, Bao PP, et al. Estimates and prediction of prostate cancer incidence, mortality and prevalence in China, 2008[J]. Chin J Epidemiol, 2012, 33(10): 1056-1059. DOI: 10.3760/cma.J.issn.0254-6450.2012.10.014.issn.0254-6450.2012.10.014.
[17]	罗林, 王海洋, 邱凌, 等. 前列腺癌患者免疫功能指标变化及临床特征对免疫功能影响的分析[J]. 癌症进展, 2018, 16(4): 509-511. DOI: 10.11877/iissn.1672-1535.2018.16.04.32. Luo L, Wang HY, Qiu L, et al. The changes of immune function indexes and the effect of clinical features on inlmune function in patients with prostate cancer[J]. Oncology Progress Journal, 2018, 16(4): 509-511. DOI: 10.11877/iissn.1672-1535.2018.16.04.32.
[18]	Rooney C, Beral V, Maconochie N. Case-control study of prostatic cancer in employees of the United Kingdom Atomic Energy Authority[J]. BMJ, 1993, 307(6916): 1391-1397. DOI: 10.1136/bmj.307.6916.1391.
[19]	张连升, 郭伟, 金鑫, 等. 饮食、环境危险因素与前列腺穿刺活检阳性的关联[J]. 临床医学研究与实践, 2018, 3(23): 95-96, 99. DOI: 10.19347/j.cnki.2096-1413.201823043. Zhang LS, Guo W, Jin X, et al. Relationship between dietary and environment risk factors and positive puncture biopsy of prostate[J]. Clinical Research and Practice, 2018, 3(23): 95-96, 99. DOI: 10.19347/j.cnki.2096-1413.201823043.